Mylan’s ‘Investor Logic’ For Acquisition Could Support Perrigo’s Rejection
This article was originally published in The Tan Sheet
Mylan targeted Perrigo as soon as it could, after acquiring Abbott Laboratories’ non-U.S. developed markets in June 2014, says CEO Heather Bresch. Her remarks at investor conference could lend support to Perrigo’s argument that Mylan’s offer does not acknowledge the value of its Omega Pharma acquisition.
You may also be interested in...
Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.